Clinical Trial Protocol: QUILT -3.067 Amendment 1 Confidential and Proprietary 9 Phase 1b Primary Endpoint: • Incidence of treatment- emergent adverse events (AEs) and serious AEs (SAEs), graded using the National Cancer Institute (NCI) Co mmon Terminology Criteria for Adverse Events (CTCAE) Version 4.03. Secondary Endpoints: • ORR by RECIST Version 1.1.